ADAG Logo

Adagene Inc. (ADAG) Stock Forecast & Price Prediction

Live ADAG Stock Price & Analysis

Home โ€บ Stocks โ€บ China | NASDAQ | Healthcare | Biotechnology

$1.86

-0.05 (-2.62%)

12 Month Price Forecast For ADAG

$1.86
Current Price
$82.34M
Market Cap
4 Ratings
Buy 2
Hold 2
Sell 0
Wall St Analyst Ratings

Distance to ADAG Price Forecasts

+924.7%
To High Target of $19.06
+330.1%
To Median Target of $8.00
+88.2%
To Low Target of $3.50

ADAG Price Momentum

+0.5%
1 Week Change
-6.1%
1 Month Change
-45.3%
1 Year Change
-6.5%
Year-to-Date Change
-51.1%
From 52W High of $3.80
+6.9%
From 52W Low of $1.74

๐Ÿค” Considering Adagene (ADAG)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 5, 2025 7:24 PM UTC

ADAG Analyst Ratings & Price Targets

Based on our analysis of 4 Wall Street analysts, ADAG has a consensus that is neutral. The median price target is $8.00, with forecasts ranging from $3.50 to $19.06. Currently, there are 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings.

With ADAG currently trading at $1.86, the median price forecast suggests a 330.1% upside. The most optimistic forecast comes from at , projecting a 924.7% upside, while at provides the most conservative target, suggesting a 88.2% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

ADAG Analyst Consensus

2
Buy
2
Hold
0
Sell

ADAG Price Target Range

Low
$3.50
Average
$8.00
High
$19.06
Current: $1.86

Latest ADAG Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for ADAG.

Date Firm Analyst Rating Change Price Target
Jan 27, 2025 HC Wainwright & Co. Arthur He Buy Maintains $8.00
Sep 18, 2024 HC Wainwright & Co. Arthur He Buy Reiterates $5.00
Jul 22, 2024 HC Wainwright & Co. Arthur He Buy Reiterates $5.00
Jun 28, 2024 HC Wainwright & Co. Arthur He Buy Reiterates $5.00
Oct 4, 2023 HC Wainwright & Co. Arthur He Buy Reiterates $5.00
Sep 1, 2023 HC Wainwright & Co. Arthur He Buy Reiterates $5.00
Apr 21, 2023 HC Wainwright & Co. Arthur He Buy Reiterates $5.00
Mar 29, 2023 HC Wainwright & Co. Arthur He Buy Reiterates $5.00
Mar 21, 2023 HC Wainwright & Co. Arthur He Buy Reiterates $5.00
Jan 24, 2023 Morgan Stanley Matthew Harrison Overweight Maintains $5.00
Dec 7, 2022 HC Wainwright & Co. Swayampakula Ramakanth Buy Initiates $5.00
Sep 9, 2022 Morgan Stanley Matthew Harrison Overweight Maintains $7.00
Feb 1, 2022 Morgan Stanley Matthew Harrison Overweight Maintains $15.00
Jan 6, 2022 Morgan Stanley Overweight Maintains $27.00
Jul 16, 2021 Morgan Stanley Matthew Harrison Overweight Maintains $33.00
Jun 25, 2021 China Renaissance Buy Initiates $0.00
Mar 8, 2021 Jefferies Buy Initiates $0.00
Mar 8, 2021 Morgan Stanley Overweight Initiates $0.00

Stocks Similar to Adagene Inc.

The following stocks are similar to Adagene based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Adagene Inc. (ADAG) Financial Data

Adagene Inc. has a market capitalization of $82.34M with a P/E ratio of 0.0x. The company generates $815,746 in trailing twelve-month revenue with a 0.0% profit margin.

Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -4,534.8% and return on equity of -45.7%.

Valuation Metrics

Market Cap $82.34M
Enterprise Value $30.81M
P/E Ratio 0.0x
PEG Ratio -2.7x
Price/Sales 100.9x

Growth & Margins

Revenue Growth (YoY) N/A
Gross Margin N/A
Operating Margin -4,534.8%
Net Margin 0.0%
EPS Growth N/A

Financial Health

Cash/Price Ratio +93.0%
Current Ratio 2.5x
Debt/Equity 36.7x
ROE -45.7%
ROA -19.6%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Adagene Inc. logo

Adagene Inc. (ADAG) Company Overview

About Adagene Inc.

What They Do

Develops monoclonal antibody drugs for cancer.

Business Model

The company focuses on researching, developing, and producing monoclonal antibody therapies targeting various types of cancers. It generates revenue primarily through the advancement of its product candidates through clinical trials, with potential future earnings from product sales upon successful commercialization.

Additional Information

Adagene's pipeline includes several clinical-stage candidates in various phases of testing, showcasing a robust commitment to innovative cancer treatments. The company was established in 2011 and operates from Suzhou, China, positioning itself within the rapidly growing biotechnology sector.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

174

CEO

Dr. Peter P. Luo Ph.D.

Country

China

IPO Year

2021

Adagene Inc. (ADAG) Latest News & Analysis

ADAG stock latest news image
Quick Summary

A new report titled "Global CD47 Inhibitor Drug Clinical Trials Insight & Market Opportunity Outlook 2028" is now available from ResearchAndMarkets.com, focusing on market opportunities in this sector.

Why It Matters

The report signals growth potential in the CD47 inhibitor market, attracting investor interest in biotech sectors focused on innovative cancer therapies.

Source: GlobeNewsWire
Market Sentiment: Neutral
ADAG stock latest news image
Quick Summary

Adagene Inc. will present updated clinical data on its ADG126 therapy for microsatellite stable colorectal cancer at the ASCO GI Cancers Symposium on January 25, 2025.

Why It Matters

Adagene's upcoming presentation on ADG126 could impact its stock price and investor sentiment, particularly if data shows promise for treating MSS CRC.

Source: GlobeNewsWire
Market Sentiment: Neutral
ADAG stock latest news image
Quick Summary

Adagene Inc. (ADAG) and Editas Medicine (EDIT) are being compared to sector performance for the year. Specific performance metrics were not provided in the excerpt.

Why It Matters

Performance comparisons highlight relative strength or weakness, influencing investment decisions and sentiment toward Adagene and Editas in the biotech sector.

Source: Zacks Investment Research
Market Sentiment: Positive
ADAG stock latest news image
Quick Summary

Adagene Inc. (ADAG) and ANI Pharmaceuticals (ANIP) performance compared to their sector has been reported, highlighting their relative standings in 2023.

Why It Matters

Performance comparisons highlight relative strength or weakness, influencing investment decisions. Stronger performance may attract investors, while weaker results could raise concerns.

Source: Zacks Investment Research
Market Sentiment: Negative
ADAG stock latest news image
Quick Summary

ADG126 shows enhanced safety and efficacy compared to ipilimumab, utilizing precision masking, novel ADCC mechanisms, and partial CTLA-4 blockade.

Why It Matters

ADG126's enhanced safety and efficacy over ipilimumab could lead to increased market share and revenue for its developer, potentially influencing stock performance in the biotech sector.

Source: GlobeNewsWire
Market Sentiment: Neutral
ADAG stock latest news image
Quick Summary

Adagene Inc. (Nasdaq: ADAG) will present posters at the SITC 39th Annual Meeting in Houston from Nov. 6-10, 2024, focusing on novel antibody-based therapies.

Why It Matters

Adagene's poster presentations at a major oncology conference could highlight advancements in its therapies, potentially boosting investor confidence and impacting stock performance.

Source: GlobeNewsWire
Market Sentiment: Neutral

Frequently Asked Questions About ADAG Stock

What is Adagene Inc.'s (ADAG) stock forecast for 2025?

Based on our analysis of 4 Wall Street analysts, Adagene Inc. (ADAG) has a median price target of $8.00. The highest price target is $19.06 and the lowest is $3.50.

Is ADAG stock a good investment in 2025?

According to current analyst ratings, ADAG has 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.86. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for ADAG stock?

Wall Street analysts predict ADAG stock could reach $8.00 in the next 12 months. This represents a 330.1% increase from the current price of $1.86. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Adagene Inc.'s business model?

The company focuses on researching, developing, and producing monoclonal antibody therapies targeting various types of cancers. It generates revenue primarily through the advancement of its product candidates through clinical trials, with potential future earnings from product sales upon successful commercialization.

What is the highest forecasted price for ADAG Adagene Inc.?

The highest price target for ADAG is $19.06 from at , which represents a 924.7% increase from the current price of $1.86.

What is the lowest forecasted price for ADAG Adagene Inc.?

The lowest price target for ADAG is $3.50 from at , which represents a 88.2% increase from the current price of $1.86.

What is the overall ADAG consensus from analysts for Adagene Inc.?

The overall analyst consensus for ADAG is neutral. Out of 4 Wall Street analysts, 2 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $8.00.

How accurate are ADAG stock price projections?

Stock price projections, including those for Adagene Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.